Alzheimer's Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Alzheimer's clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 55 trials

Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled143 locationsNCT06159673
Recruiting

Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease

Alzheimer's Disease(AD)Time Perception
University Hospital, Caen40 enrolled1 locationNCT07341009
Recruiting
Phase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Early Alzheimer's Disease
Merck Sharp & Dohme LLC340 enrolled70 locationsNCT07033494
Recruiting
Not Applicable

Social-cognitive Functioning: Validation of a New Neuropsychological Test

Frontotemporal Degeneration(FTD)Alzheimer's Disease(AD)Lewy Body Dementia (LBD)
Assistance Publique - Hôpitaux de Paris120 enrolled1 locationNCT05558709
Recruiting

Speech Pattern Evaluation and Analysis for Knowledge of AD

Wisconsin Alzheimer's Disease Research CenterWisconsin Registry for Alzheimer's Prevention
University of Wisconsin, Madison165 enrolled1 locationNCT06230783
Recruiting
Not Applicable

COGSCREEN II: Early Detection of Cognitive Impairment

Alzheimer's Disease(AD)
Robert Perneczky400 enrolled1 locationNCT07466394
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled26 locationsNCT06887192
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics800 enrolled412 locationsNCT05980949
Recruiting
Phase 2Phase 3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled13 locationsNCT07284472
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics380 enrolled116 locationsNCT05511363
Recruiting
Phase 3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
JYAMS PET Research & Development Limited316 enrolled2 locationsNCT07422857
Recruiting

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Memory DisordersMild Cognitive ImpairmentMemory Impairment+3 more
GAP Innovations, PBC1,200 enrolled25 locationsNCT06584357
Recruiting
Phase 2

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

DementiaAlzheimers DiseaseMild Cognitive Impairment Due to Alzheimer's Disease
Brigham and Women's Hospital16 enrolled1 locationNCT06489548
Recruiting
Not Applicable

Improving PCP Advance Care Planning for People With ADRD

DementiaAlzheimer DiseaseAging+1 more
University of Pittsburgh120 enrolled1 locationNCT06565169
Recruiting
Not Applicable

Feasibility of Wearables in Dementia Care in Rural Taiwan

Circadian RhythmAlzheimer's DementiaNeuropsychiatric Symptoms Related to Neurodegenerative Disease+2 more
China Medical University Hospital20 enrolled1 locationNCT07249918
Recruiting
Not Applicable

Autophagy-Enhancers to Reduce Sleep Disturbances

Mild Cognitive Impairment Due to Alzheimer's Disease
University Medicine Greifswald76 enrolled1 locationNCT07383311
Recruiting
Not Applicable

Quantification of Hsp90 in the Human Brain

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Parkinson's Disease (PD)
Universitaire Ziekenhuizen KU Leuven48 enrolled1 locationNCT07380204
Recruiting

UPenn Observational Research Repository on Neurodegenerative Disease

Corticobasal Syndrome(CBS)Progressive Supranuclear Palsy (PSP)Primary Progressive Aphasia(PPA)+6 more
University of Pennsylvania1,000 enrolled1 locationNCT04715399
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.320 enrolled69 locationsNCT06651567